Stock Spotlight Archives - Page 101 of 379

FridayJun 17, 2022 3:07 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Ground-Breaking Studies Opening ‘Doors Previously Closed to Disruptive New Technology’

Lexaria Bioscience Corp. (NASDAQ: LEXX) understands the shortcomings of orally administered drugs and is developing DehydraTECH(TM), a drug delivery technology that solves challenges such as poor water solubility and membrane permeability, limited absorption and unwanted tastes. “The company began developing DehydraTECH in 2014 and has since strengthened the technology as well as broadened its possible applications… Lexaria has also conducted in vitro and in vivo human and/or animal studies that have evidenced the technology’s ability to mask unwanted tastes, improve the speed of onset, increase bioavailability and brain absorption, and lower dosing – thereby reducing drug administration costs – of…

FridayJun 17, 2022 2:43 pm

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Looking to Deliver EV Batteries That Surpass Today’s Technology

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is actively testing advanced battery technology that can provide a range of 600-plus miles on a full charge. “Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space... Earlier this year, the company announced an update on its next-generation solid-state polymer battery technology, which is a significant advancement over today’s current lithium-ion batteries. ‘Mullen’s testing of solid-state polymer reveals the potential for a 15-kilowatt-hour battery pack that delivers over 600-plus miles of range and highlights an 18-minute DC fast charge,…

FridayJun 17, 2022 2:26 pm

QualityStocksNewsBreaks – FuelPositive Corporation’s (TSX.V: NHHH) (OTCQB: NHHHF) Green Ammonia System a Viable Alternative to Fertilizer Production

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is positioning to meet growing demand as recent global events, such as the war in Ukraine, have created a stark wake up call, making it clear it is about time the global fertilizer industry adopted more sustainable fertilizer production and distribution methods. “With Russia being the world’s largest exporter of fertilizers, accounting for 23% of global ammonia exports and over 40% of the world’s potash supply, reality is slowly hitting the industry on its overreliance on this country for fertilizer,” reads a recent article. “As an enterprise focused on licensing, partnership and acquisition opportunities relating…

FridayJun 17, 2022 2:12 pm

QualityStocksNewsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Eyes Accelerated Growth of B2C Businesses

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, made its foray into the business-to-consumer (“B2C”) marketplace in December following the acquisition of an 80% stake in RKings Competitions Ltd. RKings is a United Kingdom-based company and leading operator of online skill-based competitions throughout the U.K. and Ireland. A recent article reads: “Less than six months into its ownership, Golden Matrix gave RKings a robust upgrade, launching the tournament platform with added features and functionality. Expectations are that the new platform will increase both the monthly number of skill tournaments and participants, thus…

FridayJun 17, 2022 1:55 pm

QualityStocksNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Poised to Become Leading Player in RNG Space

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, recently announced the acquisition of a 50% stake in Ontario’s Project Radius. The move catapults EverGen into a whole new stratosphere of growth as the leading RNG infrastructure platform in its domicile Canadian market. “The company is forging ahead, eying opportunities to expand its market presence both internationally and in Canada. Poised to become a leading player in the burgeoning RNG space, EverGen aims to deliver on its aggressive growth strategy,” a recent article reads. “Following the letter of intent to…

FridayJun 17, 2022 12:27 pm

QualityStocksNewsBreaks – Prime Harvest Inc. Committed to Community, Diversity, Becoming California’s Preferred Cannabis Retailer

Prime Harvest, a technology-driven full-service cannabis corporation, has risen to prominence as a leader in California’s cannabis industry. “Prime Harvest is horizontally diversified across the entire cannabis value chain with business activities focused on direct-to-consumer operations, licensing acquisition, compliance management and state-wide delivery. The company continues to expand its footprint throughout California with a proven long-term strategy of investing in growth and scale of licensed assets while leveraging the power of data-driven technology across its operations,” a recent article reads. “Prime Harvest is backed by a strong business strategy and anchored by its commitment to community, diversity and becoming California’s…

ThursdayJun 16, 2022 3:58 pm

QualityStocksNewsBreaks – Kronos Advanced Technologies Inc. (KNOS) Leveraging Graphene Technology to Bring Distinct Products to Market

Kronos Advanced Technologies (OTC: KNOS) has built a reputation for offering some of the most effective, advanced, state-of-the-art air filtration and purification products. “In addition to air filtration systems, the company also offers Kronos(R)-designed graphene N95-compatible face masks made in the United States at a NIOSH-certified facility. Kronos recently announced test results from Nelson Labs demonstrating significant enhanced bacterial filtration efficiency (‘BFE’) and viral filtration efficiency (‘VFE’). According to the update, Kronos’-designed and U.S.-manufactured 5-ply graphene face masks remove 99.9% of bacteria and virus particles compared to the common and far less efficacious ASTM level 4 masks. The company believes…

WednesdayJun 15, 2022 3:06 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “The company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance,” a recent article reads. “The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset…

WednesdayJun 15, 2022 2:42 pm

QualityStocksNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Building on Its Holistic Approach to Mental Health Wellness

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties, utilizing a toolbox of innovative, therapeutic substances. “Recently, Delic announced that six of its clinic locations will launch a specialized therapy that has the potential to boost natural energy stores and immunity, brain and DNA function, and cell communication. The NAD+ (nicotinamide adenine dinucleotide) infusion therapy is administered intravenously or intramuscularly and has previously shown evidence that such treatments support the creation of new cells, neuropathways…

WednesdayJun 15, 2022 2:20 pm

QualityStocksNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the participants did not exhibit any severe adverse events as PRV-002 was well tolerated,” a recent article reads. “The completion of the safety evaluation is the latest milestone as the company journeys toward providing concussion treatment… With the phase I clinical trial, which consists of 48…

Site Search

Company Search

Category: Stock Spotlight